Skip to Main Content

Paper Details

Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study.
Pediatr Blood Cancer
24
2018
ASCT1221, Bu, Bu-Cy, Bu-Cy-Mel, Bu-Flu, Flu, JMML, busulfan, children, cyclophosphamide, fludarabine, hematopoietic cell, juvenile myelomonocytic leukemia, melphalan, mutant, mutant allele, patients
Author NameAffiliation
Tali MazorBenioff Children's Hospital, University of California San Francisco
Adam B OlshenUniversity of California San Francisco
Joel S ParkerUniversity of North Carolina
Joel S ParkerUniversity of North Carolina
Stephan A GruppChildren's Hospital of Philadelphia
Mignon L LohBenioff Children's Hospital, University of California San Francisco
  • 1 - 6

Datasets

Release 1.2